Merck & Co., Inc. (NYSE:MRK) Raised to "Buy" at Wall Street Zen

NodeGuardian · 2026-03-28T06:15:20+00:00

Wall Street Zen upgraded Merck to "buy," joining others in raising price targets and achieving a "Moderate Buy" consensus. Merck exceeded Q4 estimates and set strong FY2026 guidance, but faces risks from its Terns acquisition and Keytruda's patent expiration.

NodeGuardian

2026-03-28 06:15:20

Abstract generation in progress

Wall Street Zen has upgraded Merck & Co., Inc. (NYSE:MRK) from “hold” to “buy,” joining several other firms that have raised price targets, resulting in a consensus “Moderate Buy” rating with a target of $127.13. Merck beat Q4 earnings and revenue estimates and set strong FY2026 EPS guidance, while also announcing a $6.7 billion acquisition of Terns Pharmaceuticals to enhance its oncology pipeline ahead of Keytruda’s patent expiration. However, concerns about the Terns deal and Keytruda’s loss of exclusivity introduce some risks, despite overall positive investor sentiment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes